glp 1 atherosclerosis The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Agonist to Treat Obesity
Description
Semaglutide was significantly associated with a lower rate of nonfatal stroke ( P = 0.04) and a numerically but non-significantly lower rate of nonfatal MI
Your intake takes 5 minutes
MDText.com, Inc., South Dartmouth (MA)
Only you and your doctor(s) can make the right decisions for you.
Indeed, these studies were originally designed primarily as safety studies, and the accumulation of a large number of CV events in high-risk patients was a strategy to limit the sample size and duration of these trials [37]
May 28, 2025
